A novel tRNA-derived fragment AS-tDR-007333 promotes the malignancy of NSCLC via the HSPB1/MED29 and ELK4/MED29 axes.
AS-tDR-007333
ELK4
HSPB1
MED29
Non-small cell lung cancer
tRNA-derived fragments
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
07 05 2022
07 05 2022
Historique:
received:
23
12
2021
accepted:
21
04
2022
entrez:
7
5
2022
pubmed:
8
5
2022
medline:
11
5
2022
Statut:
epublish
Résumé
Transfer RNA-derived fragments (tRFs) are a new class of small non-coding RNAs. Recent studies suggest that tRFs participate in some pathological processes. However, the biological functions and mechanisms of tRFs in non-small cell lung cancer (NSCLC) are largely unknown. Differentially expressed tRFs were identified by tRF and tiRNA sequencing using 9 pairs of pre- and post-operation plasma from patients with NSCLC. Quantitative real-time PCR (qRT-PCR) and fluorescence in situ hybridization (FISH) were used to determine the levels of tRF in tissues, plasma, and cells. Gain- and loss-of-function experiments were implemented to investigate the oncogenic effects of tRF on NSCLC cells in vitro and in vivo. Chromatin immunoprecipitation (ChIP), luciferase reporter, RNA pulldown, mass spectrum, RNA immunoprecipitation (RIP), Western blot, co-immunoprecipitation (Co-IP) assays, and rescue experiments were performed to explore the regulatory mechanisms of tRF in NSCLC. AS-tDR-007333 was an uncharacterized tRF and significantly up-regulated in NSCLC tissues, plasma, and cells. Clinically, AS-tDR-007333 overexpression could distinguish NSCLC patients from healthy controls and associated with poorer prognosis of NSCLC patients. Functionally, overexpression of AS-tDR-007333 enhanced proliferation and migration of NSCLC cells, whereas knockdown of AS-tDR-007333 resulted in opposite effects. Mechanistically, AS-tDR-007333 promoted the malignancy of NSCLC cells by activating MED29 through two distinct mechanisms. First, AS-tDR-007333 bound to and interacted with HSPB1, which activated MED29 expression by enhancing H3K4me1 and H3K27ac in MED29 promoter. Second, AS-tDR-007333 stimulated the expression of transcription factor ELK4, which bound to MED29 promoter and increased its transcription. Therapeutically, inhibition of AS-tDR-007333 suppressed NSCLC cell growth in vivo. Our study identifies a new oncogenic tRF and uncovers a novel mechanism that AS-tDR-007333 promotes NSCLC malignancy through the HSPB1-MED29 and ELK4-MED29 axes. AS-tDR-007333 is a potential diagnostic or prognostic marker and therapeutic target for NSCLC.
Sections du résumé
BACKGROUND
Transfer RNA-derived fragments (tRFs) are a new class of small non-coding RNAs. Recent studies suggest that tRFs participate in some pathological processes. However, the biological functions and mechanisms of tRFs in non-small cell lung cancer (NSCLC) are largely unknown.
METHODS
Differentially expressed tRFs were identified by tRF and tiRNA sequencing using 9 pairs of pre- and post-operation plasma from patients with NSCLC. Quantitative real-time PCR (qRT-PCR) and fluorescence in situ hybridization (FISH) were used to determine the levels of tRF in tissues, plasma, and cells. Gain- and loss-of-function experiments were implemented to investigate the oncogenic effects of tRF on NSCLC cells in vitro and in vivo. Chromatin immunoprecipitation (ChIP), luciferase reporter, RNA pulldown, mass spectrum, RNA immunoprecipitation (RIP), Western blot, co-immunoprecipitation (Co-IP) assays, and rescue experiments were performed to explore the regulatory mechanisms of tRF in NSCLC.
RESULTS
AS-tDR-007333 was an uncharacterized tRF and significantly up-regulated in NSCLC tissues, plasma, and cells. Clinically, AS-tDR-007333 overexpression could distinguish NSCLC patients from healthy controls and associated with poorer prognosis of NSCLC patients. Functionally, overexpression of AS-tDR-007333 enhanced proliferation and migration of NSCLC cells, whereas knockdown of AS-tDR-007333 resulted in opposite effects. Mechanistically, AS-tDR-007333 promoted the malignancy of NSCLC cells by activating MED29 through two distinct mechanisms. First, AS-tDR-007333 bound to and interacted with HSPB1, which activated MED29 expression by enhancing H3K4me1 and H3K27ac in MED29 promoter. Second, AS-tDR-007333 stimulated the expression of transcription factor ELK4, which bound to MED29 promoter and increased its transcription. Therapeutically, inhibition of AS-tDR-007333 suppressed NSCLC cell growth in vivo.
CONCLUSIONS
Our study identifies a new oncogenic tRF and uncovers a novel mechanism that AS-tDR-007333 promotes NSCLC malignancy through the HSPB1-MED29 and ELK4-MED29 axes. AS-tDR-007333 is a potential diagnostic or prognostic marker and therapeutic target for NSCLC.
Identifiants
pubmed: 35526007
doi: 10.1186/s13045-022-01270-y
pii: 10.1186/s13045-022-01270-y
pmc: PMC9077895
doi:
Substances chimiques
ELK4 protein, human
0
HSPB1 protein, human
0
Heat-Shock Proteins
0
Molecular Chaperones
0
ets-Domain Protein Elk-4
146481-62-1
RNA, Transfer
9014-25-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
53Subventions
Organisme : National Natural Science Foundation of China
ID : 41977372
Organisme : National Natural Science Foundation of China
ID : 81972003
Organisme : Science and Technology Program of Guangdong Province
ID : 2017B 030301016
Organisme : Natural Science Foundation of Guangdong Province
ID : 2019A1515010210
Organisme : Natural Science Foundation of Guangdong Province
ID : 2021A1515011046
Organisme : Natural Science Foundation of Guangdong Province
ID : 2021A1515012144
Organisme : Shenzhen Science and Technology Innovation Commission
ID : JCYJ20180507182427559
Organisme : Shenzhen Science and Technology Innovation Commission
ID : JCYJ20170818100842319
Organisme : Guangdong Medical Research Foundation
ID : A2018312
Organisme : Shenzhen University
ID : 86000000210
Informations de copyright
© 2022. The Author(s).
Références
Nature. 2017 Dec 7;552(7683):57-62
pubmed: 29186115
Int J Biochem Cell Biol. 2012 Oct;44(10):1646-56
pubmed: 22571949
RNA. 2018 Aug;24(8):1093-1105
pubmed: 29844106
Cancer Lett. 2018 Apr 10;419:1-7
pubmed: 29337107
Cancer Res. 2007 Mar 1;67(5):1943-9
pubmed: 17332321
Trends Genet. 2016 Jan;32(1):42-56
pubmed: 26704082
Cell. 2017 Jan 12;168(1-2):135-149.e22
pubmed: 28086087
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741
Mayo Clin Proc. 2019 Aug;94(8):1623-1640
pubmed: 31378236
Cell. 2018 May 17;173(5):1204-1216.e26
pubmed: 29628141
Carcinogenesis. 2017 May 1;38(5):485-491
pubmed: 28449079
RNA Biol. 2013 Dec;10(12):1798-806
pubmed: 24351723
Cells. 2019 Dec 24;9(1):
pubmed: 31878360
Cell. 2015 May 7;161(4):790-802
pubmed: 25957686
Biochem Biophys Res Commun. 2020 Jan 1;521(1):220-226
pubmed: 31630804
Curr Drug Targets. 2018;19(13):1478-1490
pubmed: 28831912
Cancer Lett. 2015 May 1;360(2):114-8
pubmed: 25721081
Acta Pharmacol Sin. 2016 Sep;37(10):1273-1280
pubmed: 27397541
J Biol Chem. 2020 Sep 25;295(39):13617-13629
pubmed: 32737196
Elife. 2018 Dec 12;7:
pubmed: 30540252
Cancer. 2011 Apr 1;117(7):1516-28
pubmed: 21425153
J Clin Invest. 2021 Nov 15;131(22):
pubmed: 34779408
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21931-6
pubmed: 21106759
Nucleic Acids Res. 2016 Jul 8;44(W1):W185-93
pubmed: 27179031
Hepatology. 2019 Feb;69(2):639-652
pubmed: 30136421
J Immunol. 2018 Sep 15;201(6):1681-1691
pubmed: 30068599
Mol Cell Biol. 1999 Feb;19(2):979-88
pubmed: 9891034
Nucleic Acids Res. 2015 Jan;43(Database issue):D141-5
pubmed: 25392422
J Transl Med. 2021 Aug 9;19(1):342
pubmed: 34372882
Oncogene. 2020 Jun;39(24):4666-4680
pubmed: 32398865
Trends Pharmacol Sci. 2017 Mar;38(3):226-256
pubmed: 28012700
Sci Rep. 2016 Aug 24;6:31842
pubmed: 27555231
Nature. 2015 Feb 19;518(7539):376-80
pubmed: 25652824
Cell. 2018 Apr 5;173(2):386-399.e12
pubmed: 29625054
Cancer Res. 2017 Jun 15;77(12):3194-3206
pubmed: 28446464
Cancer Res. 2013 May 15;73(10):3109-19
pubmed: 23492367
Nat Struct Mol Biol. 2014 May;21(5):449-55
pubmed: 24704787
Cell. 2018 Sep 20;175(1):6-9
pubmed: 30217360
Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1404-9
pubmed: 23297232
Cell Death Dis. 2020 May 11;11(5):348
pubmed: 32393790
Front Cell Dev Biol. 2020 May 05;8:289
pubmed: 32432110
Breast Cancer Res. 2011 Oct 24;13(5):R101
pubmed: 22023707
Proc Natl Acad Sci U S A. 2016 May 3;113(18):5071-6
pubmed: 27071132